Efficacy observation of finasteride combined with M-receptor antagonist in the treatment of benign prostatic hyperplasia with overactive bladder
10.3760/cma.j.issn.0254-9026.2013.10.019
- VernacularTitle:非那雄胺联合M受体拮抗剂治疗前列腺增生合并膀胱过度活动症的疗效
- Author:
Jianlong WANG
;
Fei WANG
;
Ben WAN
;
Jianye WU
- Publication Type:Journal Article
- Keywords:
Prostatic hyperplasia;
Urinary bladder,overactive
- From:
Chinese Journal of Geriatrics
2013;32(10):1095-1097
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of finasteride and M-receptor antagonist (tolterodine tartrate release tablet) in patients with benign prostatic hyperplasia (BPH) with overactive bladder (OAB).Methods 40 patients with BPH and OAB were treated with finasteride (5 mg,Qd) and tolterodine tartrate release tablet (4 mg,Qd) for 6 months.The clinical effects were evaluated by the International Prostate Symptom Score (IPSS),Overactive Bladder Symptom Score (OABSS),urgency rating scale,maximum flow rate,voiding volume,prostate volume before and after treatment.Results Compared with before treatment,the IPSS,OABSS,urgency rating scale,maximum flow rate,voiding volume,prostate volume were improved [(11.8±1.4) vs.(19.2±2.1),(4.6±2.6) vs.(9.3±1.8),(1.2±1.9) times/week vs.(4.7±1.0) times/week,(14.5±2.7) ml/s vs.(10.2±2.2) ml/s,(25.2±2.6) ml vs.(34.6±3.2) m1,(46.2±2.2) ml vs.(57.6±1.3) ml,all P＜0.05] after treatment.No urinary retention and other adverse reactions were found.Conclusions Finasteride combined with M-receptor antagonist (tolterodine tartrate release tablet) is an effective and safe therapeutic method for patients with BPH and OAB.
